Endoscopic Ultrasound-FNA Predicts Survival in Pancreatic Endocrine Tumours | Gastroenterology
LinkedIn Login

Connect healthcare products, companies and hospitals with your LinkedIn network.

Facebook Login

Interact with your Facebook network around healthcare products, companies and hospitals.

Login With Facebook
MedicExchange Login

Enjoy Premium Access as a MedicExchange Member.

       Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Facebook Twitter Linkedin
Facebook: MedicExchange
Twitter: MedicExchange
Communities Abdominal Pelvic Endoscopic Ultrasound-FNA Predicts Survival in Pancreatic Endocrine Tumours

Endoscopic Ultrasound-FNA Predicts Survival in Pancreatic Endocrine Tumours

Specialties

EUS-FNA findings predict 5-year survival in patients with PET and this may help to better guide the therapeutic approach for these patients.

In the November issue of GIE: Gastrointestinal Endoscopy, a study examining endoscopic ultrasound (EUS) demonstrated the accuracy of EUS-fine needle aspiration (FNA) in diagnosing and determining the malignant behaviour of pancreatic endocrine tumours.

In the first study, researchers from the Institute Paoli-Calmettes, Marseilles, France, set out to determine the value of EUS-FNA for the diagnosis of PET s and for classifying the underlying malignant potential of these tumours based on the proposed World Health Organization (WHO) classification.

Although EUS-FNA is often used for diagnosing PET, there are no data on its accuracy in determining the malignant potential of PET s and in applying the WHO classification.

The single-center, retrospective cohort study involved 86 patients who had been diagnosed with PETs and submitted to an EUS-FNA from January 1999 to August 2008.

Overall, in 90% of patients in this study, PET was diagnosed with EUS-FNA. The sensitivity did not vary with tumour size, type, location, or the presence of hormonal secretion.

Of 86 patients, 35% were submitted to surgical resection. There was a fair correlation between the WHO classification obtained by EUS-FNA and that obtained by surgery in the 24 patients who had records on both procedures available.

All 10 patients classified as having an endocrine carcinoma by EUS-FNA had the diagnosis confirmed by surgery. The five-year survival rates were 100% for endocrine tumours, 68% for well-differentiated endocrine carcinomas, and 30% for poorly differentiated endocrine carcinomas.

The researchers concluded that EUS-FNA is a safe and highly accurate technique for diagnosing PET and that it is possible to determine the potential malignant behaviour of a PET in specimens obtained by EUS-FNA by applying the WHO classification.

EUS-FNA findings predict 5-year survival in patients with PET and this may help to better guide the therapeutic approach for these patients.

Source: ASGE

You can discuss more about Gastroenterology & Endoscopy and related topics in our Gastroenterology & Endoscopy Group.

 

Related Articles